Acorda Therapeutics, Inc. Stock Price, News & Analysis

Acorda Therapeutics reported its Q4 and full year 2021 financial results, highlighting AMPYRA net revenue of $22.5 million, down from $25.3 million in Q4 2020, and a full year revenue of $84.6 million compared to $98.9 million in 2020. INBRIJA saw a revenue increase of 22% year-over-year with $10.4 million in Q4 and $29.6 million for the year. The company expects 2022 AMPYRA revenue between $68-$78 million and operating expenses of $110-$120 million. Acorda also retired its short-term convertible debt and projects cash flow neutrality by end of 2022.

Acorda Therapeutics (NASDAQ: ACOR) plans to host a webcast/conference call on March 9, 2022, at 4:30 p.m. ET, to discuss its fourth quarter and year-end 2021 financial results. Participants can register via a provided link. A replay of the call will be available starting at 7:30 p.m. ET the same day until April 8, 2022. Acorda focuses on therapies for neurological disorders, including the inhaled treatment INBRIJA for Parkinson's disease and AMPYRA for improved walking in multiple sclerosis. Forward-looking statements highlight potential risks affecting product sales and operational performance.

Acorda Therapeutics (NASDAQ: ACOR) will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation, featuring CEO Ron Cohen, will be available on-demand starting January 10 at 7:00 am ET. Investors can access the webcast via the company's website. Acorda focuses on therapies for neurological disorders, including INBRIJA, approved for treating OFF episodes in Parkinson's patients, and AMPYRA, used for improving walking in multiple sclerosis patients. The company warns of potential risks regarding product sales and market competition.

Acorda Therapeutics (NASDAQ: ACOR) announced the appointment of John Varian to its board of directors, effective January 1, 2022. Varian's extensive biopharma experience, including previous roles as CEO and CFO, is expected to enhance the company's strategic goals, including optimizing its financial structure and accelerating growth for INBRIJA, a treatment for Parkinson's disease. CEO Ron Cohen expressed optimism about Varian's contributions, while Varian himself acknowledged Acorda's significant opportunities and challenges ahead.

Acorda Therapeutics has signed a distribution agreement with Esteve Pharmaceuticals to commercialize INBRIJA in Germany. The deal includes a €5 million upfront payment and sales-based milestones, providing Acorda with a significant double-digit percentage of sales. INBRIJA, a treatment for Parkinson's disease, is expected to launch in mid-2022. Currently, there are around 400,000 people with Parkinson's in Germany, highlighting the potential market. Acorda is also in discussions for distribution rights in other European countries.

Acorda Therapeutics (Nasdaq: ACOR) reported Q3 2021 net revenue of $7.8 million for INBRIJA, a 34% increase from Q3 2020, and $20.0 million for AMPYRA, down from $27.3 million. The company announced a partnership with ESTEVE to commercialize INBRIJA in Germany, with a €5 million upfront payment. Leadership changes include Michael Gesser as CFO and Neil Belloff as General Counsel. Acorda aims to be cash flow positive by the end of 2022. The company reported a GAAP net loss of $27.1 million for the quarter, and cash reserves decreased to $62 million.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a Webcast to discuss its third quarter 2021 update and financial results on November 9 at 4:30 p.m. ET. Participants can register via a provided link to receive a confirmation email with Webcast details. A replay will be accessible from 7:30 p.m. ET on the same day until December 9. Acorda develops therapies for neurological disorders, including INBRIJA® for Parkinson's and AMPYRA® for multiple sclerosis. The press release also outlines potential risks affecting the company's market position and product sales.

Acorda Therapeutics (ACOR) announced a corporate restructuring plan aimed at reducing costs by 15% in headcount, primarily to align operating expenses with expected revenue. The company anticipates annualized savings exceeding $20 million, beginning in 2022, despite incurring approximately $3.0 million in pre-tax charges for severance. Additionally, management changes were revealed, with Lauren Sabella appointed as Chief Operating Officer and Kerry Clem as Chief Commercial Officer. The changes come after substantial progress in sales and debt retirement amid pandemic challenges.

Acorda Therapeutics reported a 36% increase in INBRIJA net sales for Q2 2021, reaching $6.4 million, compared to $4.7 million in Q2 2020. AMPYRA net revenue declined to $21.8 million from $26.1 million year-over-year. R&D expenses decreased to $2.4 million, while SG&A expenses fell to $32.4 million. The company reported a GAAP net loss of $22.9 million, up from $17.4 million in the same quarter last year. Acorda expects AMPYRA revenues for 2021 between $75 - $85 million, but remains cautious on INBRIJA's projected peak revenue due to pandemic uncertainties.